Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor

机译：为lumacaftor / ivacaftor治疗的F508del-CFTR纯合的囊性纤维化患者的长期健康结局建模

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background:Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. However, long-term survival benefits of lumacaftor/ivacaftor (LUM/IVA) cannot yet be quantified. Simulation models can provide predictions about long-term health outcomes. In this study, we aimed to project long-term health outcomes of LUM/IVA plus standard care (SC) in patients with CF homozygous for F508del-CFTR.

机译：背景：Lumacaftor / ivacaftor联合疗法对F508del-CF跨膜电导调节剂（CFTR）突变的纯合性囊性纤维化（CF）患者有效且通常安全。但是，尚不能量化lumacaftor / ivacaftor（LUM / IVA）的长期生存益处。模拟模型可以提供有关长期健康结果的预测。在这项研究中，我们旨在预测F508del-CFTR纯合CF患者的LUM / IVA加标准治疗（SC）的长期健康结果。

著录项

期刊名称 Therapeutic Advances in Respiratory Disease
作者
Jaime L. Rubin; Lasair O’Callaghan; Christopher Pelligra; Michael W. Konstan; Alexandra Ward; Jack K. Ishak; Conor Chandler; Theodore G. Liou;
展开▼
作者单位

展开▼
年(卷),期 2019(13),-1
年度 2019
页码 1753466618820186
总页数 23
原文格式 PDF
正文语种
中图分类呼吸生理学;
关键词
cystic fibrosis ivacaftor lumacaftor percent predicted forced expiratory volume in 1 second (ppFEV1) simulation model survival survival projection;

机译：囊性纤维化;ivacaftor;lumacaftor;1秒内预测的强制呼气量百分比（ppFEV1）;模拟模型;存活率;存活率预测;

相似文献

外文文献
中文文献
专利

1. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor [J] . Jaime L. Rubin, Lasair O’Callaghan, Christopher Pelligra, Therapeutic advances in respiratory disease. . 2019,第13期

机译：为lumacaftor / ivacaftor治疗的F508del-CFTR纯合的囊性纤维化患者的长期健康结局建模
2. INFECTIONS IN F508DEL-CFTR HOMOZYGOUS CYSTIC FIBROSIS PATIENTS TREATED WITH LUMACAFTOR/IVACAFTOR IN A NORTHERN ITALIAN CYSTIC FIBROSIS CENTER [J] . Colombo C., Cariani L., Sottotetti S., Pediatric Pulmonology . 2018,第Suppla2期

机译：F508DEL-CFTR纯合囊性纤维化纤维化患者在意大利囊性纤维化中心洛马夫特/ IVACAFTOR治疗的F508DEL-CFTR纯合囊性纤维化患者
3. INFECTIONS IN F508DEL-CFTR HOMOZYGOUS CYSTIC FIBROSIS PATIENTS TREATED WITH LUMACAFTOR/IVACAFTOR IN A NORTHERN ITALIAN CYSTIC FIBROSIS CENTER [J] . Colombo C., Cariani L., Sottotetti S., Pediatric Pulmonology . 2018,第Suppla2期

机译：F508DEL-CFTR纯合囊性纤维化纤维化患者在意大利囊性纤维化中心洛马夫特/ IVACAFTOR治疗的F508DEL-CFTR纯合囊性纤维化患者
4. OMICS approaches to reveal Burkholderia cenocepacia adaptive strategies to long-term residence in the lungs of cystic fibrosis patients under antibiotic therapy [C] . Madeira Andreia, Mira Nuno P, Santos Pedro M, 1st Portuguese Meeting in Bioengineering . 2011

机译：OMICS方法揭示在抗生素治疗下囊性纤维化患者长期驻留在肺泡中的伯克霍尔德菌种的适应策略
5. Socioeconomic status, adherence to therapy, and health outcomes in pediatric patients with cystic fibrosis [D] . Oates, Gabriela R. 2015

机译：社会经济地位，依赖于囊性纤维化的儿科患者的治疗和健康结果
6. Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation [O] . Deborah M. Cholon, Charles R. Esther Jr, Martina Gentzsch -1

机译：Lumacaftor-ivacaftor治疗纯合F508del-CFTR突变的囊性纤维化患者的疗效
7. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3 trial [O] . Ratjen, F, Hug, C, Marigowda, G, 2017

机译：Lumacaftor和ivacaftor对6至11岁患有F508del-CFTR纯合性囊性纤维化患者的疗效和安全性：随机，安慰剂对照，3期临床试验

Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅